Introduction
Peripheral artery disease (PAD) affects approximately 230 million people worldwide, according to a 2025 systematic analysis in The Lancet Global Health. In the United States alone, an estimated 8–12 million adults have PAD, with prevalence rising to 20% among those over 70. Despite its high prevalence and strong association with cardiovascular mortality (3–6 times higher risk of heart attack and stroke), PAD remains dramatically underdiagnosed: the American Heart Association (AHA) estimates that only 25% of PAD patients receive a diagnosis, and up to 50% are asymptomatic or have atypical symptoms.
The consequences of undiagnosed PAD are severe. Patients with critical limb ischemia (CLI) — the most advanced form of PAD — face a 25% amputation rate and 25% mortality rate within one year of diagnosis. Yet PAD is detectable through simple, non-invasive measurements: the ankle-brachial index (ABI), a ratio of systolic blood pressure at the ankle to that at the arm, with an ABI ≤0.90 indicating significant arterial obstruction.
For B2B buyers — vascular surgery clinics, cardiology practices, primary care networks, home health agencies, and medical device distributors — wearable technology that enables continuous, non-invasive monitoring of peripheral circulation represents a significant clinical and commercial opportunity. This article explores the clinical rationale, technology landscape, and OEM procurement considerations for medical wearables in vascular disease management.
The Pathophysiology of PAD: Why Continuous Monitoring Matters
PAD is caused by atherosclerosis — the buildup of fatty plaques in the arteries supplying the legs — that progressively narrows the arterial lumen and restricts blood flow. The clinical spectrum ranges from asymptomatic disease to intermittent claudication (exercise-induced leg pain that resolves with rest) to critical limb ischemia (rest pain, non-healing wounds, gangrene).
The progression from asymptomatic PAD to CLI can occur over months to years, but acute deterioration — due to plaque rupture, thrombosis, or embolism — can happen within hours. Traditional diagnostic methods (ABI measurement, duplex ultrasound, CT angiography) are performed intermittently in clinical settings and cannot capture the day-to-day trajectory of disease progression or the acute events that precede CLI.
Continuous wearable monitoring offers the potential to detect:
- Gradual decline in perfusion: Early warning of disease progression before symptoms develop
- Acute ischemic events: Sudden changes in perfusion parameters that may indicate arterial occlusion
- Exercise-induced ischemia: Objective documentation of the hemodynamic response to walking
- Post-revascularization monitoring: Detection of restenosis or graft failure after angioplasty, stenting, or bypass surgery
Wearable Technologies for Vascular Monitoring
1. Photoplethysmography (PPG)-Based Perfusion Assessment
PPG sensors — the same technology used in smart rings and smartwatches for heart rate and SpO₂ monitoring — can assess peripheral perfusion by analyzing the amplitude and waveform morphology of the pulsatile signal. Reduced PPG amplitude, delayed waveform upstroke, and diminished dicrotic notch are characteristic of impaired arterial inflow.
A 2025 study in the Journal of Vascular Surgery demonstrated that multi-wavelength PPG (green, red, infrared) from a finger-worn sensor could detect PAD with 84% sensitivity and 79% specificity compared to ABI as the reference standard, using machine learning analysis of PPG waveform features. While not yet a replacement for ABI, this technology enables continuous, passive screening that can identify patients who should be referred for formal diagnostic testing.
2. Wearable Ankle-Brachial Index (ABI) Devices
Traditional ABI measurement requires a Doppler probe and blood pressure cuff — equipment that is not available in most primary care settings. Automated oscillometric ABI devices have simplified the process but remain clinic-based. Emerging wearable ABI devices combine inflatable cuffs (or cuffless PPG sensors) at the ankle and arm with automated algorithms to calculate ABI in under 3 minutes, enabling point-of-care screening in primary care, pharmacy, and community health settings.
3. Transcutaneous Oxygen Pressure (TcPO₂) Monitoring
TcPO₂ measures the partial pressure of oxygen at the skin surface, reflecting the oxygen delivery capacity of the local microcirculation. A TcPO₂ below 30 mmHg indicates severe ischemia and a high risk of non-healing wounds. While traditional TcPO₂ measurement requires heated electrodes in a clinical setting, research is underway on wearable optical sensors that can estimate tissue oxygenation through near-infrared spectroscopy (NIRS). A 2024 proof-of-concept study in Scientific Reports demonstrated that a wearable NIRS sensor on the foot could detect clinically significant changes in tissue oxygenation during controlled limb ischemia.
4. Skin Temperature Monitoring for Perfusion Assessment
Skin temperature is a simple but useful surrogate for perfusion. A temperature difference of ≥2°C between the left and right foot, or between the foot and the ambient temperature-controlled reference, suggests unilateral arterial insufficiency. Continuous temperature monitoring using wearable sensors can detect perfusion changes over time, providing an early warning of deteriorating circulation.
5. Activity and Gait Monitoring for Claudication Assessment
Intermittent claudication is the classic symptom of PAD, but patient-reported walking distance is unreliable. Wearable accelerometers can objectively measure:
- Pain-free walking distance: The distance walked before claudication pain begins
- Maximum walking distance: The total distance walked before pain forces a stop
- Gait changes: Claudication causes characteristic gait alterations (reduced stride length, increased stance time) that can be detected by accelerometer-based gait analysis
A 2025 study in Circulation demonstrated that wearable-derived claudication distance was more reproducible (ICC 0.89) than patient-reported distance (ICC 0.62) and was a stronger predictor of 12-month revascularization need.
B2B Deployment Models
Primary Care Screening Programs
PAD screening is recommended by the AHA/ACC for all adults over 65 and for adults over 50 with diabetes or smoking history. Yet fewer than 30% of eligible patients receive screening, primarily due to time constraints and lack of equipment in primary care. Wearable or point-of-care ABI devices can close this screening gap.
Home Health and Post-Revascularization Monitoring
Patients who have undergone lower-extremity revascularization (angioplasty, stenting, or bypass) require lifelong surveillance for restenosis. Traditional surveillance involves duplex ultrasound every 3–6 months, but restenosis can develop between visits. Wearable perfusion monitoring at home can detect early signs of restenosis, triggering earlier intervention and potentially reducing the rate of graft failure and repeat revascularization.
Wound Care and CLI Management
Patients with CLI and non-healing wounds require frequent assessment of perfusion and wound healing progress. Wearable sensors that monitor tissue oxygenation, temperature, and perfusion can provide objective data to guide wound care decisions and predict healing outcomes.
OEM Requirements for Vascular Monitoring Wearables
- Multi-wavelength PPG: Green, red, and infrared for comprehensive perfusion assessment
- High signal-to-noise ratio: For reliable waveform analysis in low-perfusion states
- Continuous temperature monitoring: ±0.1°C resolution for detecting perfusion-related temperature changes
- Clinical validation: Documented sensitivity and specificity against ABI or duplex ultrasound
- EHR integration: For seamless incorporation into clinical workflows
- Regulatory compliance: FDA 510(k) or CE marking for vascular assessment claims
The Geyan Technology Innovation Advantage
Geyan Technology Innovation’s smart ring and smartwatch platforms — featuring multi-wavelength PPG sensors, continuous temperature monitoring, and clinical-grade signal processing — provide a foundation for peripheral vascular monitoring applications. Our OEM/ODM services include sensor algorithm customization, companion app development, and regulatory documentation support for CE, FCC, and FDA submissions.
Contact Geyan Technology Innovation to discuss your vascular monitoring wearable program.
📧 Email: jine@xdunmedical.com
📞 Phone: +86-13544254314
🌐 Web: xdunmedical.com
—
Sources: The Lancet Global Health PAD Prevalence (2025); AHA PAD Statistics; Journal of Vascular Surgery (2025); Scientific Reports (2024); Circulation (2025); AHA/ACC PAD Guidelines; WHO Cardiovascular Disease Fact Sheet.*